(Q46133466)

19 December 2017

title

Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study (English)

1 reference

19 December 2017

author name string

Young Beom Jeong

1

1 reference

19 December 2017

Keun Sang Kwon

2

1 reference

19 December 2017

Sang Deuk Kim

3

1 reference

19 December 2017

Hyung Jin Kim

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

3 February 2009

1 reference

19 December 2017

published in

Urology

1 reference

19 December 2017

volume

73

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

802-806

1 reference

19 December 2017

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Benign prostatic hyperplasia: a progressive disease of aging men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Longitudinal changes in peak urinary flow rates in a community based cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Natural history of prostatism: risk factors for acute urinary retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Symptoms and signs of prostatism as risk factors for prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The long-term outcome of medical therapy for BPH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.046

10.1016/J.UROLOGY.2008.10.046

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

release_6pihrvhjwzgnzhgsgwgf6ufu3q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6pihrvhjwzgnzhgsgwgf6ufu3q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 December 2017